EMPLICITI 440 MG — DIN 02455919

What is EMPLICITI?

EMPLICITI 440 MG contains ELOTUZUMAB : 440 MG. It is listed in the Health Canada Drug Product Database under DIN 02455919, held by BRISTOL-MYERS SQUIBB CANADA, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 12-Dec-2023. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.

How much does Elotuzumab cost around the world?

Elotuzumab is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Czechia publishes a max producer price (ex-factory); Italy publishes a ex-factory (classe H). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

Market	Price basis published there	Brands	Packs listed
Norway	max AUP (pharmacy retail)	1	4
Australia	ex-manufacturer	1	2
Czechia	max producer price (ex-factory)	1	2
Italy	ex-factory (classe H)	2	2

10 pack listings across 5 brand entries and 4 price bases, refreshed 08 Sep 2026. Ranges span every Elotuzumab pack in that market, so a high figure is usually a larger pack rather than the same product.

This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.

Is there a generic Elotuzumab in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

Only one market authorization holder has a Canadian DIN containing Elotuzumab — 2 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.

Market authorization holder	DINs	Marketed	Brand names	Position
BRISTOL-MYERS SQUIBB CANADA	2	0	EMPLICITI	No marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label	440 MG
Dosage form	POWDER FOR SOLUTION
Route	INTRAVENOUS

Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.

Substance and classification

Active substance	Elotuzumab
ATC code	L01FX08
Biosimilar biologic	No

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)	02455919
DIN (unpadded, as printed on some documents)	2455919
Brand name	EMPLICITI
Generic / active ingredient	ELOTUZUMAB : 440 MG
Market authorization holder	BRISTOL-MYERS SQUIBB CANADA
Health Canada schedule	Prescription
ATC code	L01FX08
ATC anatomical main group	L — Antineoplastic and immunomodulating agents
ATC therapeutic subgroup	L01FX
Current status	CANCELLED PRE MARKET
Status date	12-Dec-2023
Status source	Live Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

0 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

Product	Strength	Form	Holder	Health Canada status	DIN
EMPLICITI	340 MG	POWDER FOR SOLUTION	BRISTOL-MYERS SQUIBB CANADA	CANCELLED PRE MARKET	02455927

2 · Same class — other molecules in ATC L01FX

Molecule	Canadian brands	DINs	Marketed	Sourceable
Polatuzumab Vedotin	POLIVY	2	2	Yes
Teclistamab	TECVAYLI	2	2	Yes
Belantamab Mafodotin	BLENREP	2	2	Yes
Glofitamab	COLUMVI	2	2	Yes
Talquetamab	TALVEY	2	2	Yes
Tarlatamab	IMDELLTRA	2	2	Yes
Elranatamab	ELREXFIO	2	2	Yes
Enfortumab Vedotin	PADCEV	2	2	Yes
Epcoritamab	EPKINLY	2	2	Yes
Blinatumomab	BLINCYTO	1	1	Yes

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC L01F

ATC subgroup	Molecules	DINs	Marketed
L01FD	Pertuzumab · Trastuzumab · Trastuzumab Deruxtecan · Trastuzumab Emtansine	18	16
L01FG	Bevacizumab · Ramucirumab	14	14
L01FF	Atezolizumab · Avelumab · Cemiplimab · Dostarlimab · Durvalumab · +3 more	14	12
L01FA	Obinutuzumab · Ofatumumab · Rituximab	11	8
L01FC	Daratumumab · Isatuximab	5	5
L01FY	Nivolumab And Relatlimab · Pertuzumab And Trastuzumab	4	4
L01FE	Cetuximab · Necitumumab · Panitumumab	5	3
L01FB	Inotuzumab Ozogamicin	1	1

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02455919. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.